Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

ShiftPixy, Inc. (NASDAQ: PIXY) is “One to Watch”

The rise of the sharing economy model and gig economy, empowered by mobile IT and big data, has rapidly transformed an antiquated labor market, where the average independent worker often ended up dependent on temp agencies (which aggregated this labor pool) in order to find employment. However, this evolution of the labor market has come […]

Algae Dynamics Corp. (ADYNF) Collaborates with University of Western Ontario

Research finds that higher levels of the brain chemical GABA can reverse negative effects such as schizophrenia and depression Professor Steven Laviolette, who spearheaded the study, hopes that GABA-increasing cannabinoid compounds developed with industrial partners from this research could lead to clinical trials “in the next few years” Algae Dynamics Corp. has signed a collaborative […]

India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

Four drug candidates in the pipeline Potential sales of Alzheimer’s drugs run to billions Hyalolex heading for clinical trials India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed […]

 

From Our Blog

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

February 4, 2026

Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well existing treatments work, […]

Rotate your device 90° to view site.